Progressive multifocal leukoencephalopathy pathophysiology: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Progressive multifocal leukoencephalopathy}} | {{Progressive multifocal leukoencephalopathy}} | ||
{{CMG}} | {{CMG}} | ||
== | |||
==Pathophysiology== | |||
PML is a [[demyelinating disease]], in which the [[myelin]] sheath covering the [[axon]]s of nerve cells is gradually destroyed, impairing the transmission of nerve impulses. It affects the white matter, which is mostly composed of axons from the outermost parts of the brain ([[Cerebral cortex|cortex]]). Symptoms include weakness or paralysis, vision loss, impaired speech, and cognitive deterioration. PML is similar to another demyelinating disease, [[multiple sclerosis]], but since it destroys the cells that produce myelin (unlike MS, in which myelin itself is attacked but can be replaced), it progresses much more quickly. Most patients die within four months of onset. | PML is a [[demyelinating disease]], in which the [[myelin]] sheath covering the [[axon]]s of nerve cells is gradually destroyed, impairing the transmission of nerve impulses. It affects the white matter, which is mostly composed of axons from the outermost parts of the brain ([[Cerebral cortex|cortex]]). Symptoms include weakness or paralysis, vision loss, impaired speech, and cognitive deterioration. PML is similar to another demyelinating disease, [[multiple sclerosis]], but since it destroys the cells that produce myelin (unlike MS, in which myelin itself is attacked but can be replaced), it progresses much more quickly. Most patients die within four months of onset. | ||
PML destroys [[oligodendrocyte]]s and produces intranuclear inclusions. | PML destroys [[oligodendrocyte]]s and produces intranuclear inclusions. | ||
| Line 7: | Line 9: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Needs overview]] | |||
[[ | |||
[[Category:Psychiatry]] | [[Category:Psychiatry]] | ||
[[Category:Mental disorders due to a general medical condition]] | [[Category:Mental disorders due to a general medical condition]] | ||
| Line 20: | Line 15: | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
{{ | {{WH}} | ||
{{ | {{WS}} | ||
Revision as of 14:36, 5 December 2012
|
Progressive multifocal leukoencephalopathy Microchapters |
|
Differentiating Progressive multifocal leukoencephalopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Progressive multifocal leukoencephalopathy pathophysiology On the Web |
|
American Roentgen Ray Society Images of Progressive multifocal leukoencephalopathy pathophysiology |
|
FDA on Progressive multifocal leukoencephalopathy pathophysiology |
|
CDC on Progressive multifocal leukoencephalopathy pathophysiology |
|
Progressive multifocal leukoencephalopathy pathophysiology in the news |
|
Blogs on Progressive multifocal leukoencephalopathy pathophysiology |
|
Risk calculators and risk factors for Progressive multifocal leukoencephalopathy pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Pathophysiology
PML is a demyelinating disease, in which the myelin sheath covering the axons of nerve cells is gradually destroyed, impairing the transmission of nerve impulses. It affects the white matter, which is mostly composed of axons from the outermost parts of the brain (cortex). Symptoms include weakness or paralysis, vision loss, impaired speech, and cognitive deterioration. PML is similar to another demyelinating disease, multiple sclerosis, but since it destroys the cells that produce myelin (unlike MS, in which myelin itself is attacked but can be replaced), it progresses much more quickly. Most patients die within four months of onset. PML destroys oligodendrocytes and produces intranuclear inclusions.